Part D Redesign and GLP-1: 2026 Out-of-Pocket Caps Explained

Introduction

The Part D redesign is the biggest improvement to Medicare drug coverage in two decades, and for GLP-1 users it’s a genuine but conditional win. The headline: your out-of-pocket spending on covered Part D drugs is now capped each year. The cap started at $2,000 in 2025 under the Inflation Reduction Act and is indexed annually, landing slightly higher for 2026. After you hit it, covered prescriptions cost you nothing for the rest of the year.

The condition: the cap applies only to covered drugs. And the oldest frustration in Medicare remains in force: Part D has long excluded drugs prescribed for weight loss alone. So whether the redesign saves you thousands or nothing depends entirely on why your GLP-1 is prescribed and whether your plan covers it for that reason.

This guide explains how the redesigned benefit works, which GLP-1 situations it helps, the installment program most enrollees still haven’t heard of, and what the 2026 federal pricing deals may change.

At TrimRx, we work with plenty of patients on Medicare whose coverage doesn’t reach their weight management goals. If that’s you, the free assessment quiz shows what a self-pay program costs in about five minutes.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did the Part D Redesign Actually Change?

Three structural changes, phased in across 2024-2025 and now standard:

Quick Answer: The Inflation Reduction Act redesigned Medicare Part D: out-of-pocket drug costs are now capped annually (the cap launched at $2,000 in 2025 and is indexed upward yearly, sitting slightly above that for 2026).

1. An annual out-of-pocket cap. The notorious coverage gap (“donut hole”) and the old catastrophic phase with 5% endless coinsurance are gone. Once your covered drug spending hits the cap ($2,000 at launch in 2025, indexed slightly upward each year after), you pay $0 for covered drugs through December.
2. The Medicare Prescription Payment Plan. You can opt to spread your out-of-pocket costs into level monthly payments across the year instead of paying large sums at the pharmacy counter in early months.
3. Rebalanced plan economics. Insurers and manufacturers now bear more cost in the catastrophic phase, which has pushed plans toward tighter formularies and more utilization management, the quiet downside of the redesign.

For anyone taking expensive brand medications, the cap transforms the worst-case year. Before redesign, a senior on multiple brand drugs could spend $7,000 to $10,000 out of pocket. Now the ceiling is a known number you can budget around.

Does the Out-of-pocket Cap Apply to Wegovy® or Zepbound® for Weight Loss?

For weight loss as the sole indication, generally no, because the cap only counts spending on drugs your plan covers, and Part D plans have historically been barred from covering medications used solely for weight loss. A drug your plan doesn’t cover generates cash-pay spending that never touches your cap.

This is the single most misunderstood point in Medicare GLP-1 coverage. The redesign capped costs; it didn’t expand what’s coverable. Those are separate policy levers.

The movement is happening on the second lever. The federal pricing agreements announced in late 2025 included commitments toward Medicare access for GLP-1 weight loss therapy with copays reported around $50 a month, phasing in through 2026. As of mid-2026, implementation details (which plans, which criteria, what timeline) were still settling, so treat that as a developing improvement to verify with your plan rather than a benefit to count on today.

Which GLP-1 Prescriptions DO Count Toward the Cap?

The covered-indication routes, which are how most Medicare patients legitimately get these molecules:

• Type 2 diabetes: Ozempic®, Mounjaro®, Rybelsus®, and Trulicity® are standard Part D formulary drugs for diabetes. Copays vary by plan and tier, and every dollar counts toward your cap.
• Cardiovascular risk reduction: after the SELECT trial (Lincoff 2023, NEJM) showed semaglutide 2.4 mg cut major cardiovascular events by 20% in people with obesity and established cardiovascular disease, Wegovy® gained that indication, and CMS confirmed Part D plans could cover it for that use. Plans typically require documented cardiovascular disease plus BMI criteria and prior authorization.
• Sleep apnea: Zepbound®’s approval for moderate-to-severe obstructive sleep apnea in adults with obesity (from the SURMOUNT-OSA program) opened another coverable indication, plan rules permitting.
• Chronic kidney disease context: the FLOW trial (Perkovic 2024, NEJM) showed semaglutide slowed kidney disease progression in diabetics, strengthening coverage cases in that population.

If you qualify under any of these, your GLP-1 is cap-eligible, and an expensive medication paradoxically becomes more affordable, since brand GLP-1 copays accelerate you toward the cap, after which everything covered is free.

How Does the Cap Math Work for a Real GLP-1 Patient?

Take a 68-year-old with type 2 diabetes and heart disease on Ozempic®, a statin, an anticoagulant, and blood pressure medication. Suppose her Ozempic® copay is $120 a month on her plan’s preferred brand tier and her other drugs add $80 monthly.

Under the redesigned benefit she pays roughly $200 a month until her cumulative out-of-pocket hits the year’s cap, which happens around month ten on those numbers. Months eleven and twelve: $0 for everything covered. Her annual exposure is the cap, full stop, where the pre-redesign structure could have left her paying coinsurance all year.

Now add the Prescription Payment Plan: instead of $200 in January, she can elect level monthly installments of her projected annual total, roughly $170 a month spread evenly. Same total, no painful months. For retirees on fixed Social Security income, the smoothing is sometimes worth more than the cap itself.

One planning note: hitting the cap early (common with brand GLP-1s) means the back half of the year is the time to fill everything coverable, complete dose adjustments, and stock allowable supplies, since marginal covered costs are zero.

What’s the Catch in the Redesigned Benefit?

Formulary tightening. Because plans now carry more of the catastrophic-phase cost, they’ve responded exactly as economists predicted: more prior authorization, more step therapy, more quantity limits, and more aggressive tier placement, with expensive GLP-1s as primary targets. Some plans also trimmed which GLP-1s they prefer, steering patients to one molecule over another.

Practical defenses:

• Check the formulary every October. Plans change GLP-1 tiers and rules annually, and the Annual Enrollment Period (October 15 to December 7) is your switch window. A plan that covers your exact drug at a decent tier is worth more than a famous brand name on the card.
• Expect prior authorization and prepare it. Diagnosis codes, BMI history, cardiovascular documentation for SELECT-based coverage. Denials for missing paperwork are the most common and most fixable kind.
• Use Extra Help if income-eligible. The Low-Income Subsidy caps copays at a few dollars and stacks with the redesign.

Key Takeaway: Covered GLP-1 uses do benefit: Ozempic® and Mounjaro® for diabetes, and Wegovy® for cardiovascular risk reduction after SELECT, all count toward the cap.

Does Medicare Advantage Change Any of This?

Not structurally. Medicare Advantage plans with drug coverage (MA-PD) follow the same Part D rules: the same annual cap, the same installment option, the same historical weight-loss exclusion, and the same covered-indication pathways. What differs is execution: MA plans tend to run tighter prior authorization and narrower formularies than standalone Part D plans, but they also sometimes bundle weight management extras (gym benefits, nutrition counseling) on the medical side that standalone plans never offer.

Practical read: if you’re choosing between MA and original Medicare partly because of GLP-1 access, compare the specific formulary tier and PA criteria for your exact drug and indication, plan against plan, during enrollment. The Medicare Plan Finder shows drug-level costs per plan, and an hour there beats any general rule.

What If Medicare Still Won’t Cover Your GLP-1 for Weight Loss?

Then you’re a cash-pay patient for this medication, and the 2026 cash market is far kinder than it used to be. Brand direct channels (manufacturer programs and the TrumpRx federal platform) put injectables around $349 to $499 a month, with reported starting-dose pricing near $350, as of mid-2026.

Compounded GLP-1 programs through licensed 503A pharmacies typically beat that: TrimRx runs $199 a month for compounded semaglutide and $349 for compounded tirzepatide with provider oversight included, and seniors are one of our fastest-growing patient groups. Elsewhere in the established telehealth market, programs such as Ro, Henry Meds, and Mochi Health publish their own GLP-1 plans, HealthRX.com publishes plans at $99 and $149 a month with LegitScript certification (50087439) and a 30-day money-back guarantee, and FormBlends shares pricing after a consult under its personalization model. None of this spending counts toward your Part D cap, but at these prices many retirees find the monthly number manageable where $1,000+ never was.

One caution: be wary of mixing channels without telling your prescriber. Your Medicare-covered diabetes care and any self-pay weight management program need to know about each other; duplicate GLP-1 therapy is dangerous.

The Path Forward

The redesign means a Medicare patient with a covered GLP-1 indication (diabetes, cardiovascular risk, sleep apnea) now has a hard annual ceiling on drug costs plus an installment option, which is a real, bankable improvement. For weight-loss-only prescriptions, the exclusion still bites as of mid-2026, with federal pricing deals pointing toward change worth watching but not yet counting on.

So work the order: confirm whether any covered indication legitimately fits you, prepare the prior authorization properly, revisit your plan every October, and if coverage truly isn’t there, price the modern cash market before giving up. TrimRx will give you that number straight: $199 a month for compounded semaglutide programs, $349 for tirzepatide, provider included. The free assessment quiz takes five minutes.

Bottom line: Federal pricing deals reported through mid-2026 point toward broader Medicare GLP-1 access around $50 copays, which would change this picture substantially if fully implemented.

FAQ

What Is the Part D Out-of-pocket Cap for 2026?

The cap launched at $2,000 in 2025 and is indexed annually, so the 2026 figure sits modestly above $2,000. After your covered out-of-pocket spending reaches it, covered prescriptions cost $0 for the rest of the year. Your plan documents state the exact current number.

Does Medicare Cover Wegovy in 2026?

For cardiovascular risk reduction in people with obesity and established heart disease, yes, many Part D plans cover it with prior authorization, based on the SELECT trial results. For weight loss alone, the historical exclusion still applied as of mid-2026, with federal pricing deals pushing toward broader access around $50 copays. Check your specific plan.

Do My Cash Payments for a GLP-1 Count Toward the Part D Cap?

No. Only out-of-pocket spending on drugs covered by your plan accumulates toward the cap. Cash purchases through direct-pay platforms, manufacturer programs, or compounded telehealth programs sit entirely outside Medicare’s accounting.

What Is the Medicare Prescription Payment Plan?

An option (started 2025) that spreads your out-of-pocket drug costs into level monthly installments across the year instead of large pharmacy-counter payments in early months. It doesn’t reduce your total, but it smooths cash flow, which matters for fixed-income budgets carrying brand-drug copays.

How Do Seniors Afford GLP-1s for Weight Loss If Part D Won’t Pay?

The 2026 cash market: brand direct channels around $349 to $499 monthly, federal platform starting doses reported near $350, and compounded programs from roughly $99 to $349 with provider care included. TrimRx programs start at $199. HSA funds, where available, can cover prescription weight loss medication pre-tax.

Will the Weight-loss Exclusion in Part D Ever End?

Momentum says eventually. The 2025-2026 federal pricing agreements included Medicare GLP-1 access commitments, CMS has shown flexibility by allowing coverage for cardiovascular and sleep apnea indications, and obesity-treatment legislation keeps returning to Congress. As of mid-2026, treat expanded coverage as likely direction, not current benefit.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.